Fomento Economico Mexicano (FMX)vsGlaxoSmithKline PLC ADR (GSK)
FMX
Fomento Economico Mexicano
$121.20
+1.08%
CONSUMER DEFENSIVE · Cap: $40.85B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Fomento Economico Mexicano generates 2502% more annual revenue ($852.92B vs $32.78B). GSK leads profitability with a 17.8% profit margin vs 3.3%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).
FMX
Buy54
out of 100
Grade: C-
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FMX.
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 167.8% YoY
Reasonable price relative to book value
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
3.3% margin — thin
Weak financial health signals
Expensive relative to growth rate
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : FMX
The strongest argument for FMX centers on EPS Growth, Price/Book.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : FMX
The primary concerns for FMX are P/E Ratio, Profit Margin, Piotroski F-Score. Thin 3.3% margins leave little buffer for downturns.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
GSK carries more volatility with a beta of 0.30 — expect wider price swings.
FMX is growing revenue faster at 6.3% — sustainability is the question.
FMX generates stronger free cash flow (842M), providing more financial flexibility.
Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GSK scores higher overall (66/100 vs 54/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fomento Economico Mexicano
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Fomento Econmico Mexicano, SAB de CV, is a bottler of Coca-Cola brand beverages. The company is headquartered in Monterrey, Mexico.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?